Figure 3

MN1 induces myeloid leukemia in vivo. (A,B) Kaplan-Meier survival curve for R26-dnETV6^tg/tg; VaviCre^tg/+ (dEV⁺), R26-MN1^tg/tg; VaviCre^tg/+ (MV⁺) or Cre-ve MV⁻ mice. A log-rank (Mantel-Cox) test was used to compare curves from MV⁻ and MV⁺ mice and showed no significant difference (p = 0.1065). (C) Picture from the spleen of MV⁻ and MV⁺ mice. Scale bar: 1 cm. (D) Flow cytometric analysis for myeloid markers on single live CD45 + ve splenic cells from either a myeloid MV⁺ tumour or from a healthy MV⁻ control. (E) H&E-stained sections of spleen and liver from a tumour-bearing MV⁺ mouse. Arrows point to multinucleated myeloid cells. Scale bare: 50 µm. (F) Kaplan-Meier survival curve of transplanted splenic and hepatic MV⁺ myeloid leukemia cells. Inset: Bioluminescence detected in a NSG mouse that was transplanted with hepatic MV⁺ cells. (G) Dose-response curve for transplanted MV⁺ AML cells that were treated for 24 h with cytarabine (Ara-C) or the anthracycline doxorubicin.